← brief for 2026-10-15 · Slowing decline

RealxWorld Effectiveness of Targeted-Release Budesonide in IgA Nephropathy with Near-Universal SGLT2 Inhibitor Use.

Article C Peer reviewed Observational

Key takeaways

This study tracked real patients with IgA nephropathy who took a targeted budesonide drug. It shows how the drug works in daily life, not just in a controlled trial. This type of study shows a link to outcomes, but it is not proof of cause.

Who did this work

McDonnell T · Marshall WR · Rengarajan S · Allen J · Chinnadurai R · Sinha S · Kalra PA

Source

Article · PubMed, the drug frontier · 2026 Oct 15
https://pubmed.ncbi.nlm.nih.gov/42879331/